(CN) - A federal judge refused to toss Procaps' antitrust claims against collaborator Patheon, saying the drugmaker's alleged injuries are not self-inflicted simply because it "could have ducked the ...

Patheon, an Amsterdam-based contract drug developer, said in a regulatory filing it plans to raise $625 million in a public offering that analysts forecast would give the company a market value of ...

Durham-based Patheon (NYSE: PTHN) – which is set to be acquired by Massachusetts-based Thermo Fisher (NYSE: TMO) later this year – saw revenue and income jump in the second quarter of its 2017 fiscal ...

TORONTO and HIGH POINT, NC. – October 29, 2012 – Patheon Inc. (TSX: PTI), a leading provider of contract development and manufacturing services to the global pharmaceutical industry, today announced ...

Contract drug manufacturer Patheon (TSX:PTI) has won two contracts valued at $18 million to make experimental type 2 diabetes drugs for German pharmaceutical company Boehringer Ingelheim. Research ...

(Reuters) - Thermo Fisher Scientific Inc said on Monday it would buy Patheon NV, a Dutch manufacturer of drugs for clinical trials, for $5.2 billion as it seeks to complement its offerings in ...

Patheon is awaiting finalization of a $7.2 billion deal that will make it a part of Thermo Fisher Scientific, but in the meantime the CDMO is moving forward with expansion plans at sites that stretch ...

Thermo Fisher Scientific plans to acquire Patheon for approximately $7.2 billion cash, the companies said today, in a deal that expands the buyer into the contract development and manufacturing ...

Durham-based drug manufacturer Patheon on Monday announced its second acquisition in the past week, saying it will buy a 53-employee Oregon company for an undisclosed price. Patheon said that ...

In response to the company accepting a buyout offer, shares of Patheon N.V. (NYSE: PTHN) , a provider of development and manufacturing services for the pharmaceutical industry, jumped 33% as of 10:45 ...

WALTHAM, Mass. – Thermo Fisher Scientific Inc. is buying Patheon for $5.2 billion, giving the scientific instrument maker more access to the contract development and manufacturing organization market.

DURHAM, NC--(Marketwired - March 04, 2015) - Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, announced it has ...